Best Performing Stocks To Buy Right Now

Baozun Inc. (NASDAQ:BZUN) may not be a household name in the U.S., but there’s a good reason for investors to learn more about this high-flying Chinese e-commerce play.

Shares have already soared since its 2015 initial public offering: The stock has gone up 450%. It’s nearly tripled over the last year, as revenue growth has accelerated in recent quarters, and profitability has improved as the company moves to a service model. Meanwhile, the growth opportunity in Chinese e-commerce has the market salivating.

China’s largest brand e-commerce partner often draws comparisons to Shopify (NYSE:SHOP), which has also surged in recent years, but there are important differences between the two. While Shopify focuses mostly on software, Baozun offers a suite of services beyond IT, including warehousing, distribution, and customer service. Shopify tends to attract mostly small and medium-sized businesses as customers. Baozun, on the other hand, focuses on multinational companies — like Philips, Nike, and Microsoft — that need help operating their e-commerce businesses in China and navigating labyrinthine Chinese regulations.

Best Performing Stocks To Buy Right Now: MV Oil Trust(MVO)

MV Oil Trust (the Trust), incorporated on August 3, 2006, is a statutory trust. The Trust acquires and holds a term net profits interest for the benefit of the Trust unitholders. MV Partners, LLC (MV Partners) is a limited liability company engaged in the exploration, development, production, gathering and aggregation and sale of oil and natural gas, primarily in the Mid-Continent region in the United States. The Trust has interest in underlying properties consisting of MV Partner’s net interests in all of its oil and natural gas properties located in the Mid-Continent region in the states of Kansas and Colorado. These oil and gas properties include approximately 1,000 producing oil and gas wells. The Trust is managed by Bank of New York Mellon Trust Company, N.A. as Trustee. Approximately 62% of the net acres included in the Trust’s underlying properties are located in the El Dorado Area, which is in southeastern Kansas, and in the Northwest Kansas Area.

El Dorado Area

The underlying properties located in the El Dorado Area are operated on behalf of MV Partners by Vess Oil and are located in the El Dorado, Augusta and Valley Center Fields. Vess Oil Corporation (Vess Oil) is involved in infill drilling, well re-entries, plugback and deepening recompletion operations, and various types of restimulation work and equipment optimization programs to reduce the natural decline in production from these fields. The El Dorado Field is located atop the Nemaha Ridge in Central Butler County, Kansas. Up to 15 horizons contain hydrocarbons, ranging from the Admire Sands, at a depth of 650 feet, to the Arbuckle Dolomite, at a depth of 2,500 feet. The primary producing intervals are the Admire, Lansing-Kansas City, Viola, Simpson and Arbuckle. The Augusta Field covers approximately 10 square miles of Butler County, Kansas. The Trust is primarily engaged in the production at the Arbuckle interval along with the Simpson and Lansing-Kansas City intervals. The Augusta Field is an extension of t! he El Dorado Field. The Valley Center Field covers approximately 60 square miles of Sedgwick County, Kansas. The Valley Center Field production operations are located at the Viola interval, which is located at an average depth of 2,500 feet.

Northwest Kansas Area

Each of Vess Oil and Murfin Drilling Company, Inc. (Murfin Drilling) operate leases on behalf of MV Partners at the underlying properties that are located in the Northwest Kansas Area. The primary fields in this area are the Bemis-Shutts, Trapp, Ray and Hansen Fields. Vess Oil and Murfin Drilling are engaged in polymer treatment program at these fields. The Bemis-Shutts Field is located on the Fairport Anticline within the Central Kansas Uplift. The field consists of 17,080 acres in northeastern Ellis and southeastern Rooks Counties, Kansas. The Trust is engaged in the production at the Arbuckle interval at a depth of 3,300 feet and the Lansing-Kansas City interval at a depth of 2,800 feet. The Trapp Field consists of 35,900 acres in Russell and Barton Counties, Kansas. Production is primarily from the Lansing-Kansas City and Shawnee limestones and the Arbuckle dolomite. The Hansen Field is located along the crest of the Stuttgart-Huffstutor Anticline. Production from this field is primarily come from the Lansing-Kansas City limestone. The Ray Field is located on the eastern flank of the Central Kansas Uplift. Production is primarily from the Arbuckle dolomite and the Gorham sands with additional production from the Lansing-Kansas City interval along the eastern flank of the field. The Hansen and Ray Fields consist of over 7,000 acres in Philips and Norton Counties, Kansas. Murfin Drilling operates the leases held by MV Partners in the Trapp, Hansen and Ray Fields.

Advisors’ Opinion:

  • [By Stephan Byrd]

    Jones Energy (NYSE: MVO) and MV Oil Trust (NYSE:MVO) are both small-cap oils/energy companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, analyst recommendations, institutional ownership, risk and valuation.

  • [By Max Byerly]

    MV Oil Trust (NYSE: MVO) and Petroleo Brasileiro SA Petrobras (NYSE:PBR.A) are both oils/energy companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, risk, profitability and dividends.

Best Performing Stocks To Buy Right Now: Gilead Sciences, Inc.(GILD)

Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical needs in North America, South America, Europe, and the Asia-Pacific. The companys products include Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Harvoni, Sovaldi, Viread, and Hepsera products for the treatment of liver diseases. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, such as hepatitis B virus and hepatitis C virus; inflammation/oncology; serious cardiovascular; and respiratory conditions, as well as diabetic nephropathy and ebola. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company, Janssen R&D Ireland, Japan Tobacco Inc., and Galapagos NV. The company was founded in 1987 and is headquartered in Foster City, California.

Advisors’ Opinion:

  • [By ]

    Here’s one more in the same vein: Gilead Sciences (Nasdaq: GILD). This venerable biotech has been fighting to protect slumping revenue from its Hep C treatment franchise. To do so, Gilead is also going the generic route: the company, much like GSK above, is going to sell generic versions of its own medicines Epclusa and Harvoni.

  • [By Brian Feroldi, Chuck Saletta, and Todd Campbell]

    Todd Campbell: (Galapagos):This foreign-based biotech might not be on your radar. If it isn’t, it should be. The company expects data on its lead drug candidate soon, and if the data is positive, it could represent a multibillion-dollar opportunity for the company and its collaboration partnerGilead Sciences (NASDAQ:GILD).

  • [By Logan Wallace]

    Gilead Sciences (NASDAQ:GILD) and Nightstar Therapeutics (NASDAQ:NITE) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, dividends, institutional ownership and risk.

Best Performing Stocks To Buy Right Now: IEC Electronics Corp.(IEC)

IEC Electronics Corp., together with its subsidiaries, provides electronic contract manufacturing services in the United States. It specializes in the custom manufacture of circuit boards and system-level assemblies; various cable and wire harness assemblies; and precision metal components. The company offers its assemblies for use in various products, such as aerospace and defense systems, medical devices, industrial equipment, and transportation products. It serves aerospace and defense, medical, industrial, communications, and other sectors through a direct sales force, as well as through a network of manufacturers representatives. The company was founded in 1966 and is headquartered in Newark, New York.

Advisors’ Opinion:

  • [By Lisa Levin] Gainers
    Liberty TripAdvisor Holdings, Inc. (NASDAQ: LTRPA) shares jumped 31.6 percent to $12.18 following TripAdvisor Q1 earnings beat.
    ZAGG Inc (NASDAQ: ZAGG) rose 26.5 percent to $14.55 after the company posted better-than-expected Q1 earnings.
    OPKO Health, Inc. (NASDAQ: OPK) shares gained 25 percent to $4.0234 following Q1 beat.
    Axon Enterprise, Inc. (NASDAQ: AAXN) jumped 23.5 percent to $55.12 following a big Q1 beat. The company raised its fiscal 2018 sales growth guidance from 16-18 percent to 18-20 percent.
    Penn Virginia Corporation (NASDAQ: PVAC) gained 23.3 percent to $59.00 after reporting Q1 results.
    TripAdvisor, Inc. (NASDAQ: TRIP) rose 22.5 percent to $47.51 after the company reported stronger-than-expected results for its first quarter on Tuesday.
    Sears Holdings Corporation (NASDAQ: SHLD) shares surged 21.7 percent to $3.36. Amazon.com's partnership with Sears started in 2017 with an agreement to sell Kenmore-branded appliances online. On Wednesday, the companies announced an extension of their relationship to now include tire delivery and installations.
    EP Energy Corporation (NYSE: EPE) jumped 21.3 percent to $2.68 following Q1 results.
    LendingClub Corporation (NYSE: LC) surged 20.4 percent to $3.395 following better-than-expected Q1 earnings.
    Superior Industries International, Inc. (NYSE: SUP) gained 19 percent to $15.82 after reporting Q1 results.
    Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM) shares rose 18.5 percent to $8.13 following Q1 results.
    Twilio Inc. (NYSE: TWLO) rose 18.3 percent to $52.47 after the company posted strong quarterly results.
    Cerus Corporation (NASDAQ: CERS) shares jumped 18.3 percent to $6.47 following quarterly results.
    IEC Electronics Corp. (NYSE: IEC) shares climbed 17 percent to $4.68 after reporting better-than-expected quarterly earnings.
    New Relic, Inc. (NYSE: NEWR) rose 16.8 percent to $90.10 following Q4 results.
    Gulfport Energy Corporation (NASDAQ: GPOR)

Best Performing Stocks To Buy Right Now: PowerShares S&P SmallCap Health Care Portfolio(PSCH)

PowerShares S&P SmallCap Health Care Portfolio (the Fund) seeks investment results that correspond generally to the price and yield performance of the index called the S&P SmallCap 600 Capped HealthCare Index (the Underlying Index). The Underlying Index consists of common stocks of the United States healthcare companies. These are companies that are principally engaged in the business of providing healthcare-related products and services, including biotechnology, pharmaceuticals, medical technology and supplies, and facilities. The Fund will normally invest at least 90% of its total assets in common stocks that comprise the Underlying Index. The Fund will invest 25% or more of the value of its total assets in securities of issuers in an industry or group of industries to the extent that the Underlying Index concentrates in an industry or group of industries. The Funds investment adviser is Invesco PowerShares Capital Management LLC. Advisors’ Opinion:

  • [By ]

    1. Small Cap Health Care
    The top ETF of the small-cap health care sector is Invesco S&P SmallCap Health Care ETF (Nasdaq: PSCH), which is up an astounding 43% in 2018. The fund follows the S&P SmallCap 600 Capped HealthCare Index and has 80% of its assets deployed into common stocks of small-cap healthcare companies. The ETFs top three holdings are Ligand Pharmaceuticals, Neogen Corp, and HealthEquity.

Best Performing Stocks To Buy Right Now: Corcept Therapeutics Incorporated(CORT)

We are a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol. Elevated levels and abnormal release patterns of cortisol are implicated in a broad range of human disorders. Since our inception in 1998, we have been developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR). We have also discovered three structurally distinct series of proprietary, selective cortisol modulators, all of which share mifepristone’s affinity for GR but, unlike mifepristone, do not bind to the progesterone receptor, and so do not terminate pregnancy or cause other side effects associated with progesterone receptor antagonism. We have begun pre-clinical and clinical development of our lead compounds from these series.   Advisors’ Opinion:

  • [By Maxx Chatsko]

    Shares of Corcept Therapeutics (NASDAQ:CORT) gained over 11% last month, according to data provided by S&P Global Market Intelligence. The double-digit rise might seem impressive, but it comes on the heels of a report by the Southern Investigative Reporting Foundation (SIRF) that painted the company and its main profit generator, Korlym, a drug approved to treat Cushing’s syndrome, in a negative light. That caused the stock to plunge in late January. As a result, shares have posted a year-to-date loss of 6% through the first week of March.

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on Corcept Therapeutics (CORT)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Motley Fool Transcribers]

    Corcept Therapeutics Incorporated (NASDAQ:CORT)Q42018 Earnings Conference CallFeb. 25, 2019, 5:00 p.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

Leave a Reply

Your email address will not be published. Required fields are marked *